ARCHIVES

FDA Says Bristol’s UFT “Not Approvable” For Colorectal Cancer, Contrary To ODAC.

This article is from The Cancer Letter archive.

Vol. 27 No. 13 | March 30, 2001

Download PDF Visit The Full Archive

Related Articles

Drug Development: FDA Grants Breakthrough Therapy Designation to CTL019 In ALL

July 11, 2014

Tom Harkin Is New Chairman f Senate Labor-HS-Education Subcommittee

January 13, 1989

MRI Reveals Information That May Alter Treatment

December 28, 2007

Reauthorization Bill Ready For Senate Floor; Report to Panel Makes Clear Why Renewal Needed

April 22, 1988

Ovarian Cancer Symptom Indices May Need to be Re-Evaluated

January 27, 2012

GAO Investigation Of Cancer Control Focuses On Five Contracts, Finds Alleged Deficiencies

July 18, 1980